1. Association of Killer Cell Immunoglobulin-like Receptor (KIR) Genes and their HLA Ligands with Susceptibility to Takayasu Arteritis in the Iranian Population.
- Author
-
Beigmohammadi, Fereshteh, Aslani, Saeed, Kavosi, Hoda, Javinani, Ali, Mostafaei, Shayan, Pournazari, Mehran, Tasorian, Baharak, Farhadi, Elham, Hajiabbasi, Asghar, Zayeni, Habib, Khabbazi, Alireza, Jamshidi, Ahmadreza, Masooleh, Irandokht Shenavar, Tamartash, Zahra, Vojdanian, Mahdi, and Mahmoudi, Mahdi
- Subjects
KILLER cell receptors ,TAKAYASU arteritis ,IRANIANS ,LIGANDS (Biochemistry) ,HLA histocompatibility antigens ,KILLER cells ,GENOTYPE-environment interaction ,CYTOTOXIC T lymphocyte-associated molecule-4 - Abstract
Takayasu arteritis (TA) is a chronic inflammatory disorder characterized by vascular damage and fibrosis in the intima that commonly occurs in the aorta. In many damaged sites in TA patients, natural killer (NK) cells have been shown to be hyperactivated and produce inflammatory cytokines and toxic components. Killer cell immunoglobulin-like receptors (KIRs) are found on NK cells and interact with human leukocyte antigen (HLA) class I ligands to activate or suppress NK cells. The present study assessed the possible role of KIR and their HLA ligand genes in susceptibility to TA in Iranian patients. This case-control study included 50 TA patients and 50 healthy subjects. DNA was extracted from whole peripheral blood samples, and polymerase chain reaction with sequence-specific primers (PCR-SSP) was performed to recognize the presence or absence of polymorphism in 17 KIR genes and 5 HLA class I ligands in each participant. Among the KIR and HLA genes, a significant decrease was detected in the frequency of 2DS4 (full allele) in TA patients (38%) compared with healthy controls (82%) (OR=0.13, 95 CI=0.05–0.34). However, none of the KIR and HLA genotypes or the interactions between these genes were associated with susceptibility to TA. The KIR2DS4 gene might be involved in the regulation of activation as well as the production of cytotoxic mediators of NK cells in patients with TA. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF